pnb-0408 dihexa clinical trial (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the blood–brain barrier and has shown synaptogenic effects in preclinical models. The often-quoted dihexa human clinical trials studies

"Discovery of Novel Oleamide Analogues as Brain-Penetrant Positive Allosteric Serotonin 5-HT2C Receptor and Dual 5-HT2C/5-HT2A Receptor Modulators"

Purrfect for: Immunity health Kidney health Nervous system health Pancreas health, Gastrointestinal health, Cognitive health, Appetite health

[321] In 2022, Reeves's recitation of the Beat poem "Pull My Daisy" for a virtual benefit concert for Tibet House US, a nonprofit organization affiliated with the exiled Tibetan spiritual leader, the Dalai Lama, stirred a negative reaction from users on Chinese social media

A study of confidence intervals for Cohens d in within-subject designs with new proposals

In preclinical heart failure models, NNMT enzyme inhibition markedly reduced cardiac 1-MNA (by 77.1%), improved cardiac function, reduced left ventricular hypertrophy and fibrosis, and decreased pro-inflammatory gene expression